Immunocore’s Strong Growth Potential Justifies Buy Rating Despite Minor Revenue Adjustment
Analyst Tyler Van Buren from TD Cowen maintains a Buy rating on Immunocore Holdings with a $60 price target, despite a minor revenue forecast adjustment for Kimmtrak in 2025. The positive outlook is based on Immunocore's third-quarter earnings report, projecting $405 million in revenue. H.C. Wainwright also reiterated a Buy rating with a $100 price target, indicating strong growth potential and a favorable investment opportunity.
Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Immunocore Holdings. The associated price target is $60.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tyler Van Buren’s rating is based on a comprehensive analysis following Immunocore’s third-quarter earnings report. Despite a minor adjustment in the revenue forecast for Kimmtrak in 2025, the overall outlook remains positive, with a projected revenue of $405 million.
The decision to maintain a Buy rating and a DCF-based price target of $60 per share reflects confidence in the company’s financial health and future growth potential. These factors indicate a favorable investment opportunity, justifying the Buy recommendation.
In another report released on November 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.
